VascVersa commercialises Advanced Therapy Medicinal Products (ATMPs) derived from the novel Angicyte™ technology. Cell therapies are at the forefront of medicine and are recognised as one of the world’s leading technologies that drive innovation and promote productivity and economic growth.
"The ICURe programme was a fantastic experience for myself and the founders. It gave us the opportunity to travel worldwide and speak to potential customers in the healthcare and regenerative medicine space to better understand the problem and customer need."
Christina O'Neill - Founder and CEO, VascVersa
ANGICYTE: Regenerating Life
ANGICYTE provides a unique Cell Therapy for blood vessel regeneration. ANGICYTE stimulates new blood vessel formation leading to improved blood supply & long term healing. It has the potential to be used for a number of ischaemic diseases. Our first product will provide a new therapeutic solution for the active wound care market. ANGICYTE creates stable blood vessels in vitro and in vivo. It can provide a vital source of blood vessel cells for researchers studying angiogenesis or can be used to discover new drug therapies for cancer.
VascVersa is a new company recently spun out from Queen’s University Belfast (QUB). It's founders are Dr Christina O'Neill (Founder and CEO) Prof Reinhold Medina, and Prof Alan Stitt. VascVersa's goal is to create the next generation of living Advanced Therapies using our innovative Angicyte technology.